Continuing Medical Education Information
AACE Endocrine University
EU Y2 Event start date: 11/16/2023
Credit claim deadline: 12/31/2023
Statement of Need
Endocrine University® is designed to provide a forum for endocrinology fellows -in-training to enhance their endocrine curriculum, particularly in diabetes, thyroid, bone, and new technology which has become essential to the practice of endocrinology.
Target Audience
This program is intended for final year endocrine Fellows-in-Training.
Learning Objectives
By the end of the meeting, participants will be able to:
- Effectively utilize new diagnostic technology that has become essential to the practice of endocrinology.
- Apply the most up-to-date guidelines and evidence-based practices for the diagnosis and treatment of endocrine-related disorders.
- Integrate the latest evidence-based research for diagnosis and treatment of emerging areas of endocrine-related practice.
Accreditation and Designation Statements
ACCME
The American College of Endocrinology (ACE) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The American College of Endocrinology (ACE) designates this other (live virtual) activity for a maximum of 18.75 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosure and Conflicts of Interest Policy
The American Association of Clinical Endocrinologists (AACE) remains strongly committed to providing the best available evidence-based clinical information to participants of this educational activity and requires an open disclosure of any potential conflict of interest identified by our faculty members. It is not the intent of AACE to eliminate all situations of potential conflict of interest, but rather to enable those who are working with AACE to recognize situations that may be subject to question by others. All disclosed conflicts of interest are reviewed by the CME Subcommittee to ensure that such situations are properly evaluated and, if necessary, resolved. AACE educational standards pertaining to conflict of interest are intended to maintain the professional autonomy of the clinical experts inherent in promoting a balanced presentation of science. Through our review process, all AACE accredited activities are ensured of independent, objective, scientifically balanced presentations of information. Disclosure of any or no relationships will be made available for all educational activities.
Commercial Supporters
This activity is supported by educational grants from the following:
- Abbott Diabetes Care
- Novo Nordisk
- Recordati Rare Diseases
- Corcept Therapeutics
- Lilly USA, LLC
- Lilly USA, LLC
- Dexcom, Inc.
- Sandoz, Inc.
- Merck-Pfizer Diabetes Collaboration
- Amgen
- Ultragenyx Pharmaceutical
- Rhythm Pharmaceuticals
Planners
Planner Name
Sara E. Lubitz, MD, FACE
Ineligible Company
Hologic
Eli Lilly
Takeda
Amryt
Relevant Financial Relationship
Stock Ownership
Stock Ownership
Site PI Research Funding
Site PI Research Funding
Planner Name
Matthew J. Levine, MD, FACE
Ineligible Company
Abbott Laboratories
Mannkind
Novo Nordisk
Relevant Financial Relationship
Consultant
Speakers Bureau, Honoraria
All of the relevant financial relationships listed for these individuals have been mitigated. All other planners for this educational activity have no relevant financial relationships to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling or distributing healthcare products used by or on patients.
Faculty Disclosures
Faculty Name
Ejigayehu Abate, MD
Ineligible Company
Ascendis
Relevant Financial Relationship
Speakers Bureau, Consultant
Faculty Name
Brandi Addison, DO, FACE
Ineligible Company
Corcept
Eli Lilly
Novo Nordisk
Relevant Financial Relationship
Speakers Bureau
Speakers Bureau, Consultant
Speakers Bureau
Faculty Name
Robert Adler, MD
Ineligible Company
Radius Health
Relevant Financial Relationship
Research Funding to Institution
Faculty Name
Caroline Apovian, MD
Ineligible Company
Abbott Nutrition
Allergan, Inc
Altimmune, Inc
Cowen and Company, LLC
Curavit Clinical Research
EnteroMedics
Gelesis
Jazz Pharmaceuticals, Inc
L-Nutra, Inc
NeuroBo Pharmaceuticals
NIH
Novo Nordisk
Pain Script Corporation
PCORI
Real Appeal
Rhythm Pharmaceuticals
Riverview School
Roman Health Ventures, Inc
Scientific Intake Ltd. Co.
Tivity Health, Inc.
Xeno Biosciences
Zafgan Inc.
Relevant Financial Relationship
Advisory Board
Advisory Board
Advisory Board
Advisory Board
Advisory Board
Advisory Board
Advisory Board
Advisory Board
Advisory Board
Advisory Board
Research Funding
Research Funding, Advisory Board
Advisory Board
Research Funding
Advisory Board
Advisory Board
Advisory Board
Advisory Board
Advisory Board
Advisory Board
Advisory Board
Advisory Board
Faculty Name
Richard J. Auchus, MD, PhD, FACE
Ineligible Company
Adrenas Therapeutics
Corcept
Crinetics
Diurnal, LTD
H Lundbeck A/S
Janssen Pharmaceuticals
Neurocrine Biosciences
Novartis Pharmaceuticals
Novo Nordisk
OMass Therapeutics
PhaseBio Pharmaceuticals
Quest Diagnostics
Recordati Rare Diseases
Spruce Biosciences
Sparrow Pharma
Takeda
Xeris
Relevant Financial Relationship
Consultant
Research Funding, Consultant
Consultant
Research Funding
Consultant
Consultant
Research Funding
Research Funding, Consultant
Consultant
Consultant
Consultant
Consultant
Consultant
Research Funding
Research Funding
Consultant
Consultant
Faculty Name
Irina Bancos, MD
Ineligible Company
Adrenas
Corcept
HRA Pharma
Diurnal
Neurocrine
Recordati
Sparrow
Spruce
Relevant Financial Relationship
Consultant
Consultant
Consultant
Consultant
Consultant
Consultant, Research Funding
Consultant
Consultant
Faculty Name
Shalender Bhasin, MD
Ineligible Company
AbbVie
Aditum
FPT
MIB
OPKO
Transition Therapeutics
Xyone
Relevant Financial Relationship
Stock Ownership, Research Funding
Stock Options, Consultant
Stock Ownership, Research Funding
Stock Ownership, Research Funding
Stock Ownership
Stock Ownership, Research Funding
Stock Ownership
Faculty Name
Dan Bessesen, MD
Ineligible Company
Eli Lilly
Novo Nordisk
Relevant Financial Relationship
Stock Options
Stock Options
Faculty Name
John Carmichael, MD
Ineligible Company
Chiasma
Camurus Acromegaly
Novo Nordisk
Recordati
Relevant Financial Relationship
Research Funding
Consultant
Consultant
Consultant
Faculty Name
Geetha Gopalakrishnan, MD, FACE
Ineligible Company
Medtronic
Sparrow and Spruce
Relevant Financial Relationship
Research Funding
Research Funding
Faculty Name
Amir Hamrahian, MD
Ineligible Company
Corcept
HRA Pharma
Xeris Pharmaceutical
Relevant Financial Relationship
Stock Ownership
Stock Ownership
Stock Ownership
Faculty Name
Betul Hatipoglu, MD
Ineligible Company
Noom App
Sparrow Pharma
Tandem
Relevant Financial Relationship
Research Funding
Research Funding
Stock Options
Faculty Name
Mimi Hu, MD
Ineligible Company
Eli Lilly
Medical Education Resources
Medullary Thyroid Cancer Consortium Registry
Nordisk
Astra Zeneca
Relevant Financial Relationship
Stock Options, Research Funding
Stock Options
Stock Options
Stock Options
Stock Options
Faculty Name
Adriana Ioachimescu, MD, PhD, FACE
Ineligible Company
Strongbrindge
Xeris Pharma
Chiasma
Amryt
Recordati
HRA Pharma
Camurus
Relevant Financial Relationship
Stock Ownership
Stock Ownership, Research Funding, Consultant
Stock Ownership
Stock Ownership, Research Funding, Consultant
Stock Ownership, Research Funding, Consultant
Consultant
Consultant
Faculty Name
Laurence Katznelson, MD
Ineligible Company
Ascendis
Camarus
Crinetics
Novo Nordisk
Recordati
Strongbridge
Relevant Financial Relationship
Research Funding
Research Funding, Consultant
Research Funding
Consultant
Consultant
Consultant
Faculty Name
Ann Kearns, MD
Ineligible Company
Amgen
Relevant Financial Relationship
Research Funding
Faculty Name
Jennifer Kelly, DO, FACE, CCD
Ineligible Company
Radius Pharma
Ascendis
Relevant Financial Relationship
Research Funding, Consultant
Research Funding, Consultant
Faculty Name
Steven Petak, MD, JD, MACE
Ineligible Company
Alexion
Amgen
Relevant Financial Relationship
Speakers Bureau
Speakers Bureau
Faculty Name
Susan Samson, MD, PhD, FRCPC, FACE
Ineligible Company
Chiasma/Amryt
Corcept
Relevant Financial Relationship
Stock Ownership
Stock Ownership
Faculty Name
Meera Shah, MB, ChB, MRCP
Ineligible Company
Pendulum Therapeutics
Relevant Financial Relationship
Research Funding
Faculty Name
Vinaya Simha, MD, MBBS
Ineligible Company
Pfizer
Relevant Financial Relationship
Consultant
Faculty Name
Arthi Thirumalai, MD, MBBS
Ineligible Company
Fractyl Laboratories
Novo Nordisk
Relevant Financial Relationship
Research Funding
Research Funding
Faculty Name
Dace Trence, MD, MACE
Ineligible Company
Medtronic
Sanofi
Relevant Financial Relationship
Stock Options
Stock Options
Faculty Name
Anand Vaidya, MD, MMSc
Ineligible Company
Corcept
HRA Pharma
Mineralys
Relevant Financial Relationship
Consultant
Consultant
Consultant
Faculty Name
Robert Wermers, MD, FACE
Ineligible Company
Alexion
Inozyme
Relevant Financial Relationship
Research Funding
Research Funding
Faculty Name
William F. Young, Jr., MD, FACP, FACE
Ineligible Company
Bayer AG
Crinetics
Relevant Financial Relationship
Stock Ownership
Stock Ownership
Faculty Name
Kevin Yuen, MD, FRCP, FACE
Ineligible Company
Amryt
Ascendis
Corcept
Crinetics
Ipsen
Novo Nordisk
Recordati
Rani Therapeutics
Strongbridge
Xeris Pharma
Relevant Financial Relationship
Research Funding, Consultant
Research Funding
Research Funding, Speakers Bureau
Research Funding, Consultant
Consultant
Speakers Bureau, Consultant
Speakers Bureau, Consultant
Consultant
Consultant
Consultant
Faculty Name
Mihail Zilbermint, MD, FACE
Ineligible Company
ROM Tech
EMD Serono
Relevant Financial Relationship
Stock Options
Consultant
All of the relevant financial relationships listed for these individuals have been mitigated. All other faculty for this educational activity have no relevant financial relationships to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
Reviewers
None of the reviewers for this educational activity have relevant financial relationships to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling or distributing healthcare products used by or on patients.